View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 30, 2019

Exact Sciences to acquire Genomic Health for $2.8bn

Molecular diagnostics firm Exact Sciences has signed a definitive agreement to acquire genomic diagnostics maker Genomic Health for a total of approximately $2.8bn in cash and stock.

Molecular diagnostics firm Exact Sciences has signed a definitive agreement to acquire genomic diagnostics maker Genomic Health for a total of approximately $2.8bn in cash and stock.

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

As part of the deal, Genomic Health stockholders will gain $27.50 in cash and $44.50 in Exact Sciences stock, totalling $72 per share.

The merger of Exact Sciences with Genomic Health will create a cancer diagnostics-focused company with a commercial footprint across more than 90 countries.

Under the deal, Exact Sciences ’ Cologuard stool DNA test for colorectal cancer will be supported by Genomic Health ’s Oncotype DX gene expression tests meant to facilitate therapy decisions for colorectal, breast and prostate cancers.

Cologuard is said to have a total available screening market of $15bn in the US. The product recorded 94% year-over-year revenue growth in the second quarter of this year.

Exact Sciences aims to increase its share in the US colorectal cancer screening market from the current 6% to approximately 40% over the long-term.

Oncotype DX oncology and urology products are estimated to have a total available market of $2bn, with Genomic Health ‘s Oncotype IQ portfolio demonstrating 19% year-over-year overall revenue growth in the second quarter.

Following the completion of the transaction, the combined company will work to boost access to existing tests and offer new diagnostics for cancer patients.

In 2020, the combined firm is expected to see around $1.6bn in revenue and about $1.2bn of gross profit.

The deal will additionally combine the companies’ research and development (R&D) team, which will involve a total of more than 1,000 employees.

Besides enhanced clinical capabilities, the combined company will have extended presence for tests in primary care, oncology, obstetrics / gynaecology, gastroenterology and urology cancer areas.

The organisation will further leverage Genomic Health ‘s lab infrastructure in the San Francisco Bay Area, US.

Exact Sciences chairman and CEO Kevin Conroy said: “Together, with our collective resources and broader platform, we will be able to provide our existing tests to more people, while also accelerating the development and launch of future cancer diagnostic tests.”

The transaction has been approved by the boards of directors of both companies. It is subject to customary closing conditions and is expected to be completed this year.

Related Companies

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network